Please assess the completion status of the following clinical trial:

Trial Title: Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Women with a clinical diagnosis of postmenopausal osteoporosis~* Decision has been made to treat with denosumab 60 mg once every 6 months~* Have received their first injection of denosumab within 8 weeks prior to enrolling in this study.~* Appropriate written informed consent has been obtained (as required per local country regulations)~Exclusion Criteria~* Participating in ongoing or have participated in previous denosumab clinical trials~* Participation in other clinical or device trials in the last 6 months~* Contra-indicated for treatment with Prolia® according to the approved applicable local product label.~* Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: None): Patients with postmenopausal osteoporosis (PMO) who received at least 1 injection of denosumab 60 mg subcutaneously in the Czech Republic and Slovakia.

Based on this trial design, predict the completion outcome and termination type (if applicable).